When GLP-1s are used to treat obesity and diabetes, prescription drug costs may rise in the near term, but total medical costs should fall in the long run
So here are my thoughts on GLP-1 receptor agonists from a gastroenterologists perspective
How Genetic Testing Informs Your Long-Term GLP-1 Strategy Individual responses to GLP-1 medications vary significantly based on genetic factors affecting appetite regulation and glucose metabolism
Once injectable semaglutide (Ozempic) goes off-patent in 2032, there is a substantial likelihood of market erosion for Rybelsus
Similarly, 99% and 83% of patients with advanced fibrosis/cirrhosis at BL by APRI and FIB-4, respectively, improved by year 8
This class includes semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)